MK-677 Ibutamoren UK 2026 Research Reference
MK-677 Ibutamoren UK 2026 Research Reference Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption Table of Contents 1. Overview — why MK-677 is the reference oral secretagogue 2. Molecular struct
MK-677 Ibutamoren UK 2026 Research Reference
Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption
Table of Contents
1. Overview — why MK-677 is the reference oral secretagogue
2. Molecular structure and non-peptide design
3. Receptor pharmacology: GHSR-1a oral agonist
4. Pharmacokinetics and oral bioavailability
5. IGF-1 dose-response data
6. Tonic vs pulsatile somatotroph stimulation
7. Bone and muscle endpoints — the long-term trials
8. Elderly and sarcopenia research
9. Hip fracture research applications trials
10. Obesity and body-composition effects
11. HPA axis effects — cortisol, prolactin
12. Insulin sensitivity and glucose handling
13. Safety profile across long-term trials
14. Research protocol design
FAQ
References
1. Overview — why MK-677 is the reference oral secretagogue
MK-677 occupies a unique position in the growth-hormone-secretagogue research landscape. It is the only orally bioavailable, long-acting, selective ghrelin-receptor agonist with a substantial (>20 years) clinical research record. Most growth-hormone secretagogue research using injectable peptides (GHRP-6, hexarelin, ipamorelin) produces transient pulses; MK-677 produces sustained tonic activation because its half-life (4-6 hours) combined with daily oral dosing spans the full 24-hour cycle.
This tonic-activation property is both its strength (simpler dosing, broader receptor engagement) and its limitation (it does not preserve physiological GH pulsatility). For research questions where oral administration or sustained receptor activation is relevant, MK-677 is the reference molecule.
2. Molecular structure and non-peptide design
MK-677 is a non-peptide small molecule with a spiroindoline core designed at Merck in the 1990s. Systematic name: 2-amino-2-methyl-N-[(1R)-1-(1-methanesulfonylspiro[indoline-3,4′-piperidin]-1′-yl)carbonyl)-2-(phenylmethoxy)ethyl]propanamide. Molecular weight 528.67 g/mol.
The non-peptide design was a deliberate choice to achieve oral bioavailability — peptide secretagogues (ipamorelin, GHRP-6) are rapidly degraded in the GI tract and have negligible oral bioavailability. MK-677’s small-molecule structure allows standard capsule or tablet formulation with predictable enteric absorption.
3. Receptor pharmacology: GHSR-1a oral agonist
MK-677 is a selective agonist at GHSR-1a (the ghrelin receptor), with EC50 in the low nanomolar range in in vitro receptor assays. Key pharmacological properties:
Full agonist at GHSR-1a (no partial agonism)
Minimal activity at closely related receptors (motilin, neuromedin U)
No significant activity at GHRH receptor, somatostatin receptors, or classical monoamine receptors
No appreciable cortisol or prolactin elevation at standard doses
Mechanism of GH release: same as other ghrelin-receptor agonists — Gαq → PLC → IP₃/DAG → Ca²⁺ and PKC, producing somatotroph GH vesicle exocytosis. Also suppresses periventricular somatostatin release via hypothalamic GHSR-1a activation, lifting the tonic brake on GH release.
4. Pharmacokinetics and oral bioavailability
Oral bioavailability: ~60% at 25 mg dose
Tmax: 1-2 hours after oral dose
Plasma half-life: 4-6 hours
Duration of GH-releasing effect: 12-24 hours (single dose); tonic at daily steady state
Food effect: modest; high-fat meal delays Tmax by ~1 hour and reduces Cmax ~20% but does not affect total AUC
Steady state reached: 5-7 days of once-daily dosing
Primary metabolism: hepatic, CYP3A4
The 4-6 hour half-life combined with once-daily dosing produces peak-trough oscillation but with trough concentrations still pharmacologically active — hence tonic rather than pulsatile receptor activation.
5. IGF-1 dose-response data
Multiple dose-ranging studies in healthy adult and elderly cohorts show consistent IGF-1 dose-response:
5 mg daily: IGF-1 +15-25% from baseline
10 mg daily: IGF-1 +25-40%
25 mg daily: IGF-1 +40-60% (standard research dose)
50 mg daily: IGF-1 +60-90% (plateau approaching)
IGF-1 response reaches near-plateau at 25-50 mg daily. Doses >50 mg produce diminishing marginal IGF-1 response with increasing side-effect burden. Time-course: IGF-1 begins to rise within 48-72 hours; 80% of steady-state elevation by day 7; full plateau by 2-3 weeks.
6. Tonic vs pulsatile somatotroph stimulation
MK-677 produces sustained, predominantly tonic activation of GHSR-1a. Consequences:
24-hour GH AUC increases substantially (~60-100%)
Individual GH pulse amplitude increases modestly
Pulse frequency may actually increase in some cohorts
Trough GH concentrations between pulses are elevated compared to placebo
This profile differs fundamentally from the pulsatile peaks produced by CJC-1295 no-DAC + ipamorelin. For research designs where preserving sharp pulse definition is important (hepatic sex-dimorphic gene expression, JAK2-STAT5 pulse-encoded signalling), MK-677 is not the appropriate tool. For research designs where sustained IGF-1 elevation is the endpoint, MK-677 is often preferable because of its simpler oral dosing.
7. Bone and muscle endpoints — the long-term trials
MK-677 is distinguished from most secretagogues by having substantial long-term (12-24 month) trial data.
Murphy et al, 2001 (2-year study in elderly): 292 healthy elderly (65-80 years), MK-677 25 mg daily vs placebo, 2 years. Lean body mass +1.1 kg, fat mass −0.7 kg, IGF-1 sustained ~60% above baseline. Bone mineral density trends favourable but not statistically significant at 2 years (insufficient power for primary BMD endpoint).
Chapman et al, 1996-1997 (4-week dose-ranging): Established 25 mg daily as the optimal dose for IGF-1 elevation with acceptable tolerability.
Svensson et al, 1998: 70 healthy elderly men, MK-677 25 mg daily × 2 months, showed reversal of age-associated GH/IGF-1 decline without cortisol elevation.
8. Elderly and sarcopenia research
The rationale for MK-677 in sarcopenia research is that age-related GH/IGF-1 decline (somatopause) contributes to muscle loss and that restoring younger IGF-1 levels may slow or reverse the decline. Key trial data:
Lean mass: +1-1.5 kg over 12-24 months at 25 mg daily
Fat mass: −0.5 to −1 kg
Strength (grip, leg press): modest improvements, study-dependent
Functional outcomes (stair climbing, 6-minute walk): statistically significant improvements in some but not all cohorts
The magnitude of effect is modest compared to resistance exercise, but additive to exercise in combination designs.
9. Hip fracture research applications trials
A notable sub-study examined MK-677 in hip fracture research applications (Adunsky et al): post-operative hip fracture patients randomised to MK-677 25 mg or placebo for 24 weeks. Results included faster functional research applications on standard rehabilitation scales, though the trial was underpowered for the primary endpoint.
The rehabilitation context is a research niche of continuing interest because IGF-1 restoration has mechanistic rationale for muscle re-accretion after prolonged immobilisation.
10. Obesity and body-composition effects
MK-677 effects on body composition include:
Lean mass increase: 1-2 kg over 8-24 weeks at 25 mg daily
Fat mass change: modest decrease (0.5-1 kg) despite increased appetite
Body weight: typically net increase (lean mass + fluid retention exceeds fat loss)
Waist circumference: modest reduction
MK-677 is not a weight-loss agent; the appetite-stimulating ghrelin-receptor signalling typically produces net positive calorie balance that partially offsets lean mass gain. For weight-loss research, GLP-1 agonists are the appropriate class.
11. HPA axis effects — cortisol, prolactin
MK-677 selectivity at GHSR-1a gives it a clean HPA profile:
Cortisol: no significant elevation at 25 mg daily; transient morning cortisol increase of ~10-15% in some cohorts, resolving with adaptation
Prolactin: no meaningful elevation
ACTH: no significant change
This differentiates MK-677 from GHRP-6 and hexarelin (which produce significant cortisol and prolactin elevation). For research protocols requiring a clean HPA profile, MK-677 and ipamorelin are the appropriate ghrelin-mimetics.
12. Insulin sensitivity and glucose handling
Chronic MK-677 produces modest insulin resistance, mediated by the known counter-regulatory effect of elevated GH/IGF-1 on insulin signalling:
Fasting glucose: +5-10% from baseline at 25 mg daily over 12-24 months
Fasting insulin: +20-40%
HOMA-IR: typically increased by ~30%
HbA1c: typically increased by 0.1-0.3% (generally not clinically relevant in non-diabetic cohorts)
The magnitude is modest but clinically relevant in pre-diabetic or diabetic cohorts. Research protocol significance: exclude active T2DM or monitor glucose carefully in at-risk cohorts.
13. Safety profile across long-term trials
Adverse events across 12-24 month trials at 25 mg daily:
Increased appetite: 40-60% (pronounced in early weeks, adapts partially)
Peripheral oedema/fluid retention: 15-30%
Fatigue/lethargy: 10-20% (transient, first 2-4 weeks)
Muscle pain: 5-15%
Joint stiffness: 5-10%
Carpal tunnel symptoms: 3-8%
Mild transient hyperglycaemia: 10-15%
Reduced insulin sensitivity: 20-30%
Congestive heart failure signal (in elderly with pre-existing cardiac disease): reported in the hip-fracture sub-study, led to caution labels in subsequent elderly trials
No oncologic, hepatic or renal safety signals emerged in long-term trials.
14. Research protocol design
Typical UK laboratory research protocols using MK-677:
Dose: 25 mg once daily, orally; take at consistent time (commonly pre-bed, to align with the natural nocturnal GH pulse peak)
Titration: can be started at full dose; no titration required
Duration: 8-12 week study blocks for mechanistic endpoints; 24-52 week blocks for body-composition and bone endpoints
Baseline measurements: IGF-1, IGFBP-3, fasting glucose, HbA1c, insulin, lipid panel, CBC, comprehensive metabolic panel
On-treatment monitoring: IGF-1 at weeks 2, 4, 8, then every 4-8 weeks; fasting glucose and HbA1c at weeks 4, 12, then every 12 weeks
Body composition: DEXA at baseline, 12 weeks, 24 weeks
Bone endpoints: BMD (DEXA) at baseline and 24-52 weeks for bone-focused studies
Exclusion criteria: active T2DM with poor control, pre-existing CHF, active malignancy, pregnancy
FAQ
Is MK-677 a peptide or a small molecule? Small molecule (spiroindoline, MW 528.67 g/mol). It mimics ghrelin pharmacologically but is structurally unrelated to the ghrelin peptide.
Why is it orally bioavailable when injectable peptides aren’t? The non-peptide structure is not a substrate for GI proteases. Bioavailability is ~60% at 25 mg.
Does MK-677 preserve GH pulsatility? Partially. Pulse amplitude and frequency are modestly increased, but trough concentrations are also elevated — producing a predominantly tonic activation profile. For sharp-pulse research, CJC-1295 no-DAC + ipamorelin is preferred.
Can MK-677 be combined with injectable secretagogues? Mechanistically, no additive benefit from stacking MK-677 with another ghrelin-receptor agonist (same receptor). MK-677 + CJC-1295 (a GHRH analogue) is mechanistically additive and is a common research combination.
Is MK-677 anabolic? Modestly, via IGF-1 elevation. 1-2 kg lean mass gain over 12-24 months is typical at 25 mg daily. Less potent than direct GH or IGF-1 administration; less potent than rhGH combined with strength training.
Does MK-677 affect sleep? Positively in most studies. Slow-wave sleep duration is modestly increased, consistent with the natural association of GH pulses with slow-wave sleep.
Why the CHF signal in elderly trials? The hip-fracture sub-study reported increased CHF incidence in MK-677 arm. Mechanism is likely fluid retention and preload increase on a compromised myocardium. Subsequent elderly trials have excluded pre-existing CHF as a precaution.
References
Patchett AA et al. Design and biological activities of L-163,191 (MK-677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci USA 1995;92:7001–7005.
Chapman IM et al. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/IGF-1 axis in selected GH-deficient adults. J Clin Endocrinol Metab 1997;82:4249–4257.
Murphy MG et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab 1998;83:320–325.
Nass R et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults (2-year MK-677 trial). Ann Intern Med 2008;149:601–611.
Svensson J et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab 1998;83:362–369.
Adunsky A et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture. Arch Gerontol Geriatr 2011;53:183–189.
Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev 2018;6:45–53.
Cordoba-Chacon J et al. Somatotrope-specific deletion of the ghrelin receptor. Mol Endocrinol 2013;27:1731–1745.
Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005;85:495–522.
Müller TD, Nogueiras R et al. Ghrelin. Mol Metab 2015;4:437–460.
UK Research Cluster Hubs
GLP-1 Research Hub
Tirzepatide Hub
Retatrutide Hub
BPC-157 Research Hub
TB-500 Research Hub
Growth-Hormone Peptides Hub
Research-Grade Buyer’s Guide
Disclaimer: All peptides referenced are sold strictly for in vitro laboratory research use. Not for human consumption, veterinary use, food additive, cosmetic, or household purpose. Nothing in this article is medical advice. UK researchers are responsible for compliance with the Human Medicines Regulations 2012 and Misuse of Drugs Regulations 2001 where applicable.
William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.